Deconvoluting the 'omics' for organ transplantation.
Deconvoluting the 'omics' for organ transplantation.
复制标题
DOI：
10.1097/mot.0b013e32833068fb
复制
发表时间：
2009-10
影响因子：
2.2
通讯作者：
Sarwal MM
中科院分区：
文献类型：
--
作者：
Sarwal MM
对疾病诊断和预后的生物标志物的渴望从未如此强烈。随着基因组数据的可用性和蛋白质组数据的增加，生物标志物的发现变得越来越可行。本文综述了近年来发展中的“基因组学”技术在器官移植中的一些应用。随着基因组学、代谢组学、抗生素组学、肽组学和蛋白质组学等高通量“组学”技术的发展，人们已经努力了解特异性移植物损伤的潜在机制，并开发出新的急性排斥反应、慢性排斥反应和手术耐受的生物标志物。将潜在的生物标志物从实验室转移到临床不是一件容易的事情，需要免疫学家、分子生物学家、移植专家、遗传学家和生物信息学专家的共同努力。需要使用大量独立患者样本进行严格的前瞻性验证研究。适当和及时地利用不断发展的“基因组学”技术将为器官移植监测的转化研究的新时代奠定基石。
The desire for biomarkers for diagnosis and prognosis of diseases has never been greater. With the availability of genome data and an increased availability of proteome data, the discovery of biomarkers has become increasingly feasible. This article reviews some recent applications of the many evolving “omic” technologies to organ transplantation. With the advancement of many high throughput “omic” techniques such as genomics, metabolomics, antibiomics, peptidomics and proteomics, efforts have been made to understand potential mechanisms of specific graft injuries and develop novel biomarkers for acute rejection, chronic rejection, and operational tolerance. The translation of potential biomarkers from the lab bench to the clinical bedside is not an easy task and will require the concerted effort of the immunologists, molecular biologists, transplantation specialists, geneticists, and experts in bioinformatics. Rigorous prospective validation studies will be needed using large sets of independent patient samples. The appropriate and timely exploitation of evolving “omic” technologies will lay the cornerstone for a new age of translational research for organ transplant monitoring.